{
  "type": "add_node",
  "timestamp": "2025-08-14T22:16:29",
  "processed": false,
  "inputs": {
    "source_article_id": "73HC52AH3",
    "status": "rejected",
    "reject_category": "company_financials",
    "reject_failure_cat": "industry_vertical"
  },
  "details": {
    "llm_topic_proposal_raw": {
      "motivation": "The article highlights the significant impact of competition from generic L-Glutamine on Emmaus Life Sciences' revenue, indicating a need for a node that captures the macroeconomic implications of generic drug competition in the biopharmaceutical sector.",
      "id": "generic_l_glutamine_competition",
      "name": "Generic L-Glutamine Competition",
      "type": "macro",
      "level": "driver"
    },
    "topic_category": {
      "category": "company_financials",
      "motivation": "Quarterly financial results showing revenue decline due to generic competition and net income decline."
    },
    "relevance_gate": {
      "should_add": false,
      "reason": "Generic L‑Glutamine competition is a product‑level, industry‑specific issue, not a macro driver, tradable asset, policy regime, or geographic anchor. It falls under industry verticals, which are disallowed.",
      "confidence": 0.95,
      "failure_category": "industry_vertical"
    }
  },
  "id": "none"
}